Treatment of high-risk neuroblastoma
Although high-dose chemotherapy and autologous stem cell transplantation (HDCT/autoSCT) have improved the prognosis for patients with high-risk neuroblastoma (NB), event-free survival rates remain in the range of 30 to 40%, which is unsatisfactory. To further improve outcomes, several clinical trial...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Pediatric Society
2012-04-01
|
| Series: | Korean Journal of Pediatrics |
| Subjects: | |
| Online Access: | http://kjp.or.kr/upload/pdf/kjped-55-115.pdf |
| _version_ | 1818500096619184128 |
|---|---|
| author | Ki Woong Sung |
| author_facet | Ki Woong Sung |
| author_sort | Ki Woong Sung |
| collection | DOAJ |
| description | Although high-dose chemotherapy and autologous stem cell transplantation (HDCT/autoSCT) have improved the prognosis for patients with high-risk neuroblastoma (NB), event-free survival rates remain in the range of 30 to 40%, which is unsatisfactory. To further improve outcomes, several clinical trials, including tandem HDCT/autoSCT, high-dose 131I-metaiodobenzylguanidine treatment, and immunotherapy with NB specific antibody, have been undertaken and pilot studies have reported encouraging results. Nonetheless, about half of high-risk NB patients still experience treatment failure and have no realistic chance for cure with conventional treatment options alone after relapse. Therefore, a new modality of treatment is warranted for these patients. In recent years, several groups of investigators have examined the feasibility and effectiveness of reduced-intensity allogeneic stem cell transplantation (RI alloSCT) for the treatment of relapsed/progressed NB. Although a graft-versus-tumor effect has not yet been convincingly demonstrated in the setting of relapsed NB, the strategy of employing RI alloSCT has provided hope that treatment-related mortality will be reduced and a therapeutic benefit will emerge. However, alloSCT for NB is still investigational and there remain many issues to be elucidated in many areas. At present, alloSCT is reserved for specific clinical trials testing the immunomodulatory effect against NB. |
| first_indexed | 2024-12-10T20:38:20Z |
| format | Article |
| id | doaj.art-b9c0f05a9ebe4a61b9fae2a4f65f4c41 |
| institution | Directory Open Access Journal |
| issn | 1738-1061 2092-7258 |
| language | English |
| last_indexed | 2024-12-10T20:38:20Z |
| publishDate | 2012-04-01 |
| publisher | Korean Pediatric Society |
| record_format | Article |
| series | Korean Journal of Pediatrics |
| spelling | doaj.art-b9c0f05a9ebe4a61b9fae2a4f65f4c412022-12-22T01:34:28ZengKorean Pediatric SocietyKorean Journal of Pediatrics1738-10612092-72582012-04-0155411512010.3345/kjp.2012.55.4.1152012550401Treatment of high-risk neuroblastomaKi Woong Sung0Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.Although high-dose chemotherapy and autologous stem cell transplantation (HDCT/autoSCT) have improved the prognosis for patients with high-risk neuroblastoma (NB), event-free survival rates remain in the range of 30 to 40%, which is unsatisfactory. To further improve outcomes, several clinical trials, including tandem HDCT/autoSCT, high-dose 131I-metaiodobenzylguanidine treatment, and immunotherapy with NB specific antibody, have been undertaken and pilot studies have reported encouraging results. Nonetheless, about half of high-risk NB patients still experience treatment failure and have no realistic chance for cure with conventional treatment options alone after relapse. Therefore, a new modality of treatment is warranted for these patients. In recent years, several groups of investigators have examined the feasibility and effectiveness of reduced-intensity allogeneic stem cell transplantation (RI alloSCT) for the treatment of relapsed/progressed NB. Although a graft-versus-tumor effect has not yet been convincingly demonstrated in the setting of relapsed NB, the strategy of employing RI alloSCT has provided hope that treatment-related mortality will be reduced and a therapeutic benefit will emerge. However, alloSCT for NB is still investigational and there remain many issues to be elucidated in many areas. At present, alloSCT is reserved for specific clinical trials testing the immunomodulatory effect against NB.http://kjp.or.kr/upload/pdf/kjped-55-115.pdfNeuroblastomaHigh-dose chemotherapyAllogeneic stem cell transplantation |
| spellingShingle | Ki Woong Sung Treatment of high-risk neuroblastoma Korean Journal of Pediatrics Neuroblastoma High-dose chemotherapy Allogeneic stem cell transplantation |
| title | Treatment of high-risk neuroblastoma |
| title_full | Treatment of high-risk neuroblastoma |
| title_fullStr | Treatment of high-risk neuroblastoma |
| title_full_unstemmed | Treatment of high-risk neuroblastoma |
| title_short | Treatment of high-risk neuroblastoma |
| title_sort | treatment of high risk neuroblastoma |
| topic | Neuroblastoma High-dose chemotherapy Allogeneic stem cell transplantation |
| url | http://kjp.or.kr/upload/pdf/kjped-55-115.pdf |
| work_keys_str_mv | AT kiwoongsung treatmentofhighriskneuroblastoma |